Table of contents

  • Brand Names
  • Chemistry
  • Pharmacologic Category
  • Mechanism of Action
  • Therapeutic Use
  • Contraindications
  • Warnings and Precautions
  • Adverse Reactions
  • Genes that may be involved
  • Drug Interactions
  • Dosage
  • Pharmacokinetics and Pharmacodynamics
  • Special Considerations

Brand Names


Austria: Increlex; Belgium: Increlex; Bulgaria: Increlex; Cyprus: Increlex; Czech Republic: Increlex; Denmark: Increlex; Estonia: Increlex; Finland: Increlex; France: Increlex; Germany: Increlex; Greece: Increlex; Hungary: Increlex; Ireland: Increlex; Italy: Increlex; Latvia: Increlex; Lithuania: Increlex; Luxembourg: Increlex; Malta: Increlex; Netherlands: Increlex; Poland: Increlex; Portugal: Increlex; Romania: Increlex; Slovakia: Increlex; Slovenia: Increlex; Spain: Increlex; Sweden: Increlex; UK: Increlex.

North America

USA: Increlex.


Japan: Somazon.

Drug combinations


Mecasermin Rinfabate: C~1231~H~1967~N~371~O~384~S~20~. Mw: 36304.01. (1) Insulin-like growth factor I (human), complex with insulin-like growth factor-binding protein IGFBP-3 (human); (2) Complex of recombinant human insulin-like growth factor I (somatomedin C) with recombinant human insulin-like growth factor-binding protein 3. CAS-478166-15-3 (2004).

Pharmacologic Category

Somatotropin Agonists; Growth Hormone. (ATC-Code: H01AC03; H01AC05).

Mechanism of action

Mecasermin is an insulin-like growth factor (IGF-1) produced using recombinant DNA technology to replace endogenous IGF-1. Acting at receptors in liver and other tissues, endogenous growth hormone (GH) stimulates synthesis and secretion of IGF-1. In primary severe IGF-1 deficiency, growth hormone receptors in liver are unresponsive to GH, leading to reduced endogenous IGF-I concentrations and decreased growth (skeletal, cell, and organ). Endogenous IGF-1 also suppresses liver glucose production, stimulates peripheral glucose utilization and has inhibitory effect on insulin secretion.

Therapeutic use

Treatment of growth failure in children with severe primary insulin-like growth factor-1 deficiency (IGFD), or with GH gene deletions who have developed neutralizing antibodies to GH.

Pregnancy and lactiation implications

Unlabeled use


Hypersensitivity to mecasermin or any component of the formulation. Closed epiphyses. Active or suspected neoplasia.

Warnings and precautions

Might cause hypoglycemic effects. Intracranial hypertension (with headache, nausea, papilledema, visual changes, and/or vomiting) reported. Lymphoid hypertrophy reported and may lead to complications such as snoring, sleep apnea, and chronic middle-ear effusions. Progression of scoliosis might occur in children experiencing rapid growth. Patients with growth hormone deficiency may develop slipped capital epiphyses more frequently. Use with caution in diabetes or with risk factors for glucose intolerance (might decrease insulin sensitivity). Products might contain benzyl alcohol («gasping syndrome» in neonates). Not for use in secondary forms of IGF-1 deficiency (GH deficiency, malnutrition, hypothyroidism, chronic anti-inflammatory steroid therapy).



Legal Notice
Privacy Policy
Cookie Policy


Phone: +34-981-780505
Location: Sta Marta de, C. P. Babío, S/N, 15165 Bergondo, A Coruña

Copyright © 2023 WAGEM

Add to cart